

Primary Website References

<http://www.phppo.cdc.gov/nltn/default.aspx>

NLTN website with educational programs and more....

<http://www.phppo.cdc.gov/dls/master/default.asp>

MASTER website for antimicrobial susceptibility testing

<http://www.asm.org/division/c/index.htm>

ASM Division C (clinical microbiology) website includes

“Askit” feature.. ask an “expert” about any question related to clinical microbiology!!!

“Division C Listserve” –join to see Q&A asked/answered by your peers!!!

<http://www.cdc.gov/mmwr/>

CDC MMWR – go here to subscribe for free!

http://www.cdc.gov/ncidod/dhq/ar_visavrsa.html

CDC website for VISA/VRSA

<http://www.phppo.cdc.gov/clia/default.asp>

CLIA regulations

<http://www.fda.gov/cdrh/ode/631.html>

FDA website with requirements for FDA clearance of AST devices

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>

FDA website with list of FDA cleared diagnostic products; select Panel = “microbiology”

<http://www.fda.gov/cder/approval/index.htm>

FDA website with lists of newly approved drugs and some information on older drugs

<http://www.tufts.edu/med/apua/>

Alliance for Prudent Use of Antibiotics (APUA)

Texts and Other References

Abramowicz, M. (ed). 2004. Treatment guidelines from The Medical Letter, choice of antibacterial drugs. The Medical Letter, Inc. Vol. 2 (issue 19) March 2004:13-26.

Gilbert, D. N., R. C. Moellering, G. M. Eliopoulos, and M. A. Sande (eds). 2005. The Sanford Guide to Antimicrobial Therapy, 2005. 35th ed. Antimicrobial Therapy, Inc., Hyde Park, VT. (www.Sanfordguide.com)

Isenberg, H. I. (ed). 2004. Clinical Microbiology Procedures Handbook, 2nd edition. Section 5. ASM Press, Washington, DC. (www.asmpress.org)

Good review of mechanisms of resistance...

Livermore, D. M., T. G. Winstanley, and K. P. Shannon. 2001. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother. 48:87-102. (2004 version with minor updates can be found at www.bsac.org.uk ...select “susceptibility testing”, then “guide to AST”, then “chapter 11”)

Mandell, G. L., R. G. Douglas, R. Dolin and J. E. Bennett. 2005. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 6th edition. Churchill Livingstone, Philadelphia.

Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken, (eds). 2003. Manual of Clinical Microbiology, 8th ed. pp. 1037-1212. ASM Press, Washington, DC. (www.asmpress.org)

CLSI Standards (www.clsi.org)

- M2-A9 (M2). 2006. Performance standards for antimicrobial disk susceptibility tests. Ninth edition. Approved Standard.
- M7-A7 (M7). 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Seventh edition. Approved Standard.
- M100-S16 (M100). 2006. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement.
- M23-A2. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; Approved Guideline.
- M39-A2. 2005. Analysis and presentation of cumulative antimicrobial susceptibility test data. Approved Guideline.
- M45-P. 2005. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Proposed Guideline.

Portions were reproduced with permission, from CLSI publication M100-S16—Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement (ISBN 1-56238-588-7). Copies of the current edition may be obtained from Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Select References

1. Anguera, I., A. Del Rio, J. M. Miro, X. Matinez-Lacasa, et. al. 2005. *Staphylococcus lugdunensis* infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles. *Heart.* 91:e10.
2. Arroyo, L. A., A. Garcia-Curiel, M. E. Pachon-Ibanez, A. C. Llanos, M. Ruiz, J. Pachon, and J. Aznar. 2005. Reliability of the E-test method for detection of colistin resistance in clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol.* 43:903-905.
3. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. *Circulation.* 111:e394-434.
4. Denton, M. and K.G. Kerr. 1998. Microbiological and clinical aspects of infection associated with *Stenotrophomonas maltophilia*. *Clin Microbiol Rev.* 11:57-80.
5. Endimiani, A., F. Luzzaro, G. Brigante, M. Perilli, G. Lombardi, G. Amicosante, G. M. Rossolini, and A. Toniolo. 2005. *Proteus mirabilis* bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. *Antimicrob Agents Chemother.* 49:2598-2605.
6. Fraser, A., A. Gafter-Gvili, M. Paul, and L. Leibovici. 2005. Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomized trials. *Eur J Clin Microbiol Infect Dis.* 24:172-181.

7. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, and F. C. Tenover. 2003. Epidemiological and microbiological characterization of infections caused by *Staphylococcus aureus* with reduced susceptibility to vancomycin, United States, 1997-2001. *Clin Infect Dis.* 36:429-439.
8. Hogardt, M., S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann. 2004. Pitfalls of polymyxin antimicrobial susceptibility testing of *Pseudomonas aeruginosa* isolated from cystic fibrosis patients. *J Antimicrob Chemother.* 54:1057-1061.
9. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant *Staphylococcus aureus* with reduced vancomycin susceptibility. *Clin Infect Dis.* 38:521-528.
10. Jorgensen, J. H., S. A. Crawford, and K. R. Fiebelkorn. 2005. Susceptibility of *Neisseria meningitidis* to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. *J Clin Microbiol.* 43:3162-3171.
11. Landman, D., S. Bratu, M. Alam, and J. Quale. 2005. Citywide emergence of *Pseudomonas aeruginosa* strains with reduced susceptibility to polymyxin B. *J Antimicrob Chemother.* 55:954-957.
12. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. *Int J Antimicrob Agents.* 25:11-25.
13. Swenson, J. M., F. C. Tenover, and the Cefoxitin Disk Study Group. 2005. Results of disk diffusion testing with cefoxitin correlate with presence of *mecA* in *Staphylococcus* spp. *J Clin Microbiol.* 43:3818-3823.
14. Tenover, F. C., R. N. Jones, J. M. Swenson, B. Zimmer, S. McAllister, and J. H. Jorgensen. 1999. Methods for improved detection of oxacillin resistance in coagulase-negative staphylococci: results of a multicenter study. *J Clin Microbiol.* 37:4051-4058.
15. Tenover, F. C. 2005. The real vancomycin-resistant *Staphylococcus aureus* has arrived. *Clin Microbiol Newsletter.* 27:35-40.